Trials / Completed
CompletedNCT00305435
Safety Study of AMG 531 in Japanese Subjects With ITP
An Open Label Phase 2 Study Evaluating the Safety of Starting Dose of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.
Detailed description
The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Romiplostim (AMG-531) | Romiplostim (AMG-531) |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2006-03-22
- Last updated
- 2024-07-05
Source: ClinicalTrials.gov record NCT00305435. Inclusion in this directory is not an endorsement.